Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

A spatial view of tumor neoantigen recognition

Published

on

Nature Biotechnology, Published online: 22 July 2026; doi:10.1038/s41587-026-03203-3

The cell-by-cell interactions between neoantigen-expressing tumor cells and tumor-specific T cells remained largely unexplored. A single-cell spatial transcriptomics framework enables mapping of neoantigen-expressing tumor cells and tumor-infiltrating T cells, as well as T cell receptor sequencing. This approach reveals distinct immune niches in the tumor microenvironment and their properties that determine tumor-specific responses.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity

Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity

Published

on

As biologics, biosimilars and GLP-1s drive demand for sterile drug products, CMOs and CDMOs are investing in fill-finish, lyophilization, inspection and packaging capacity to keep pace with a dynamic injectable market.​ ​Read More

Continue Reading

Uncategorized

Biotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls out

Published

on

The FDA’s new investigational new drug pilot program—one part of HHS’s broader clinical trial modernization initiatives—has lofty goals to expedite first-in-human trials of novel drugs, but experts say it won’t tip the scales much on its own.

Continue Reading

Uncategorized

5 companies advancing ATTR assets in the wake of Wainua’s fail

Published

on

The Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals’ antisense therapy in transthyretin amyloid cardiomyopathy last month left the space reeling—and readjusting. BioSpace looks at five contenders and where they currently stand.

Continue Reading
Advertisement

Trending